ArticleBlood2019
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.International journal of molecular sciences · 2024Pooled it
- Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.JAMA oncology · 2026Trial
- Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.Leukemia · 2026Trial
- Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.Blood advances · 2023Trial
- Pan-cancer expression, methylation, and prognostic significance of α7 nicotinic acetylcholine receptor in tumor immunology.Biochemistry and biophysics reports · 2026Article
- Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.British journal of haematology · 2026Article
- Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.Blood cancer journal · 2026Article
- MCRS1 is associated with immunosuppressive microenvironments in pan-cancer and promotes hepatocellular carcinoma malignant phenotypes.Translational cancer research · 2025Article
- Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell of origin and patient outcomes.Cell reports. Medicine · 2025Article
- Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses.Leukemia · 2025Article
- CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition.Nature communications · 2025Article
- Tumor-Associated Macrophages as Key Modulators of Disease Progression in Diffuse Large B-Cell Lymphoma.Biomedicines · 2025Review
- Integration of gene mutations in risk prognostication for watch-and-wait follicular lymphoma patients initiating first-line treatment.HemaSphere · 2025Article
- Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma.Current treatment options in oncology · 2025Review
- Migrasome Marker Epidermal Growth Factor Domain-SpecificBiomedicines · 2025Article
- Pan-cancer analysis reveals ELFN1 as a novel prognostic biomarker and immunotherapeutic target associated with tumor microenvironment remodeling and promoting malignant phenotypes in colorectal cancer.Frontiers in oncology · 2025Article
- Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.Leukemia & lymphoma · 2025Article
- Utilizing Clinical Transformation Criteria for Prognostic Stratification in Follicular Lymphoma Prior to Initial Immunochemotherapy.Hematology reports · 2024Article
- PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes.International journal of biological sciences · 2024Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
Although recent advances in molecular genetics have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIPI score, the impact on treatment has been limited. We aimed to assess the prognostic significance of copy-number aberrations (CNAs) and copy-neutral loss of heterozygosity (cnLOH) identified by chromosome genomic-array testing (CGAT) at FL diagnosis using prospectively collected clinical trial specimens from 255 patients enrolled in the SWOG study S0016. The impact of genomic aberrations was assessed for early progression (progressed or died within 2 years after registration), progression-free survival (PFS), and overall survival (OS). We showed that increased genomic complexity (ie, the total number of aberration calls) was associated with poor outcome in FL. Certain chromosome arms were critical for clinical outcome. Prognostic CNAs/cnLOH were identified: whereas early progression was correlated with 2p gain (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.